Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-03-22
2011-03-22
Cordero Garcia, Marcela M (Department: 1654)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C514S021300
Reexamination Certificate
active
07910102
ABSTRACT:
Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.
REFERENCES:
patent: 3691016 (1972-09-01), Patel
patent: 3941763 (1976-03-01), Sarantakis
patent: 3969287 (1976-07-01), Jaworek et al.
patent: 4083368 (1978-04-01), Freezer
patent: 4195128 (1980-03-01), Hildebrand et al.
patent: 4229537 (1980-10-01), Hodgins et al.
patent: 4247642 (1981-01-01), Hirohara et al.
patent: 4330440 (1982-05-01), Ayers et al.
patent: 4351337 (1982-09-01), Sidman
patent: 4686283 (1987-08-01), Nestor, Jr. et al.
patent: 4847325 (1989-07-01), Shadle et al.
patent: 4849224 (1989-07-01), Chang et al.
patent: 4906159 (1990-03-01), Sabo et al.
patent: 4906169 (1990-03-01), Chien et al.
patent: 4911916 (1990-03-01), Cleary
patent: 4925673 (1990-05-01), Steiner et al.
patent: 4925677 (1990-05-01), Feijen
patent: 4983395 (1991-01-01), Chang et al.
patent: 4994439 (1991-02-01), Longenecker et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5023084 (1991-06-01), Chien et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5171264 (1992-12-01), Merrill
patent: 5206344 (1993-04-01), Katre et al.
patent: 5252714 (1993-10-01), Harris et al.
patent: 5284656 (1994-02-01), Platz et al.
patent: 5302697 (1994-04-01), Goodey et al.
patent: 5346701 (1994-09-01), Heiber et al.
patent: 5397702 (1995-03-01), Cahalan et al.
patent: 5446090 (1995-08-01), Harris
patent: 5460820 (1995-10-01), Ebert et al.
patent: 5484895 (1996-01-01), Meister et al.
patent: 5494895 (1996-02-01), Garcia et al.
patent: 5516523 (1996-05-01), Heiber et al.
patent: 5605702 (1997-02-01), Teillaud et al.
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5662925 (1997-09-01), Ebert et al.
patent: 5672688 (1997-09-01), Kobayashi et al.
patent: 5714142 (1998-02-01), Blaney et al.
patent: 5739208 (1998-04-01), Harris
patent: 5739277 (1998-04-01), Presta et al.
patent: 5763478 (1998-06-01), Baker et al.
patent: 5783208 (1998-07-01), Venkateshwaran et al.
patent: 5792451 (1998-08-01), Sarubbi et al.
patent: 5827655 (1998-10-01), Chandy et al.
patent: 5900461 (1999-05-01), Harris
patent: 5919455 (1999-07-01), Greenwald et al.
patent: 5932462 (1999-08-01), Harris et al.
patent: 5990237 (1999-11-01), Bentley et al.
patent: 6022952 (2000-02-01), Weiner et al.
patent: 6077680 (2000-06-01), Kem et al.
patent: 6096891 (2000-08-01), Carr et al.
patent: 6245740 (2001-06-01), Goldenberg et al.
patent: 6267964 (2001-07-01), Nygren et al.
patent: 6273086 (2001-08-01), Ohki et al.
patent: 6335178 (2002-01-01), Weiner et al.
patent: 6342225 (2002-01-01), Jones et al.
patent: 6451986 (2002-09-01), Pettit
patent: 6548644 (2003-04-01), Pettit
patent: 6551821 (2003-04-01), Kandel et al.
patent: 6552170 (2003-04-01), Thompson et al.
patent: 6602498 (2003-08-01), Shen
patent: 6610281 (2003-08-01), Harris
patent: 6632928 (2003-10-01), Neville et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 6689749 (2004-02-01), Lebrun et al.
patent: 6703485 (2004-03-01), Kandel et al.
patent: 6740743 (2004-05-01), Herrmann et al.
patent: 6768002 (2004-07-01), Herrmann et al.
patent: 6774106 (2004-08-01), Theill et al.
patent: 6818418 (2004-11-01), Lipovsek et al.
patent: 6849714 (2005-02-01), Bridon et al.
patent: 6861405 (2005-03-01), Desir et al.
patent: 6887470 (2005-05-01), Bridon et al.
patent: 6892728 (2005-05-01), Helgesson et al.
patent: 6894025 (2005-05-01), Harris
patent: 6900317 (2005-05-01), Trunk et al.
patent: 6905688 (2005-06-01), Rosen et al.
patent: 6926898 (2005-08-01), Rosen et al.
patent: 6932962 (2005-08-01), Bäckström et al.
patent: 6946134 (2005-09-01), Rosen et al.
patent: 6989365 (2006-01-01), Fleer et al.
patent: 7005436 (2006-02-01), Lloyd et al.
patent: 7029909 (2006-04-01), Uemura et al.
patent: 7096942 (2006-08-01), de Rouffignac et al.
patent: 7288254 (2007-10-01), Neville et al.
patent: 7348004 (2008-03-01), Peters et al.
patent: 7381408 (2008-06-01), Mezo et al.
patent: 7404956 (2008-07-01), Peters et al.
patent: 2003/0069170 (2003-04-01), Soltero et al.
patent: 2003/0069395 (2003-04-01), Sato et al.
patent: 2003/0104400 (2003-06-01), Ruben et al.
patent: 2003/0191056 (2003-10-01), Walker et al.
patent: 2003/0195154 (2003-10-01), Walker et al.
patent: 2004/0039167 (2004-02-01), Sabatier et al.
patent: 2004/0044188 (2004-03-01), Feige et al.
patent: 2004/0121959 (2004-06-01), Boone et al.
patent: 2005/0054051 (2005-03-01), Rosen et al.
patent: 2005/0054570 (2005-03-01), Rosen et al.
patent: 2007/0071764 (2007-03-01), Sullivan et al.
patent: 2007/0105199 (2007-05-01), Yan et al.
patent: 0 219 716 (1987-04-01), None
patent: 0 315 456 (1994-06-01), None
patent: 0 668 353 (1995-08-01), None
patent: 0 668 354 (1995-08-01), None
patent: 0 473 084 (1995-11-01), None
patent: 0 469 074 (1996-07-01), None
patent: 0 575 545 (2003-05-01), None
patent: WO 88/06451 (1988-09-01), None
patent: WO 92/02634 (1992-02-01), None
patent: WO 95/03065 (1995-02-01), None
patent: WO 95/13312 (1995-05-01), None
patent: WO 96/05309 (1996-02-01), None
patent: WO 96/05309 (1996-02-01), None
patent: WO 96/11953 (1996-04-01), None
patent: WO 96/32478 (1996-10-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 98/23639 (1998-06-01), None
patent: WO 98/39363 (1998-09-01), None
patent: WO 99/24055 (1999-05-01), None
patent: WO 99/38008 (1999-07-01), None
patent: WO 00/38651 (2000-07-01), None
patent: WO 00/38652 (2000-07-01), None
patent: WO 00/69900 (2000-11-01), None
patent: WO 01/83525 (2001-11-01), None
patent: WO 02/11801 (2002-02-01), None
patent: WO 02/098446 (2002-12-01), None
patent: WO 02/100248 (2002-12-01), None
patent: WO 2004/017918 (2004-03-01), None
patent: WO 2004/026329 (2004-04-01), None
patent: WO 2004/043396 (2004-05-01), None
patent: WO 2004/110472 (2004-12-01), None
patent: WO 2005/047337 (2005-05-01), None
patent: WO 2006/002850 (2006-01-01), None
patent: WO 2006/036834 (2006-04-01), None
patent: WO 2006/042151 (2006-04-01), None
patent: WO 2006/116156 (2006-11-01), None
patent: WO 2007/022070 (2007-02-01), None
patent: 2007048037 (2007-04-01), None
patent: WO 2007/045463 (2007-04-01), None
Hruby. Designing peptide receptor agonists and antagonists. Nature Reviews. Drug Discovery, 2002. vol. 1, pp. 847-858.
Bednarek et al., “Chemical synthesis and structure-function studies of margatoxin, a poten inhibitor of voltage-dependent potassium channel in human T lymphocytes”, Biochemical and Biophysical Research Communications, 198(2): 619-625, (1994).
Judge et al., “Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatment”, Pharmacology and Therapeutics, Elsevier, GB, 111(1): 224-259, (2006).
Legros, et al., “Influence of a NH2-terminal extension on the activity of KTX2, a K<+> channel blocker purified fromAndroctonus australisscorpion venom”, FEBS Letters, Elsevier, Amsterdam, NL, 417(1): 123-129, (1997).
Tytgat, J. et al., “A unified nomenclature for short-chain peptides isolated from scorpion venoms: alpha-KTx molecular subfamilies”, Trends in Pharmacological Sciences, Elsevier, Haywarth, GB, 20(11): 444-447, (1999).
USPTO Office Communication mailed Jul. 6, 2009 for U.S. Appl. No. 11/978,076.
USPTO Office Communication mail Jul. 15, 2009 for U.S. Appl. No. 11/978,110 .
USPTO Office Communication mail Jul. 22, 2009 for U.S. Appl. No. 11/978,119.
USPTO Office Communication mail Aug. 27, 2009 for U.S. Appl. No. 11/978,105.
Applicants' Restriction Requirement Response filed Aug. 5, 2009 for U.S. Appl. No. 11/978,110.
Applicants' Restriction Requirement Response filed Aug. 5, 2009 for U.S. Appl. No. 11/978,076.
Applicants' Restriction Requirement
Adler Beverly S.
Arora Khare Taruna
Gegg, Jr. Colin V.
Hu Shaw-Fen Sylvia
Martin Francis H.
Amgen Inc.
Cordero Garcia Marcela M
Steinberg Nisan A.
LandOfFree
Methods of using conjugated toxin peptide therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using conjugated toxin peptide therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using conjugated toxin peptide therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2623757